knowledge -WSS

knowledge

author：comprehensive 2025-09-28 21:11:42 - browse：73

A sign of Lilly on the top of its biotechnology center — coverage from STAT — Adobe

Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by Novo Nordisk.

In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora alfa, had a 1.34% reduction in blood sugar levels, while people on the comparator daily insulin degludec, sold as Tresiba by Novo, had a 1.26% lowering. That resulted in patients having blood sugar levels, known as A1C readings, of 6.87% and 6.95%, respectively.

In a separate 26-week trial of type 2 patients who have been using insulin, those on efsitora and the comparator daily insulin glargine, sold by Lilly as Basaglar and Sanofi as Lantus, both saw A1C reductions of 1.07%, resulting in blood sugar levels of 7.12% and 7.11%, respectively.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： How redistricting in 6 states could affect who controls Congress

WSS

FDA struggles to regulate food additives, sometimes for decades

Neutralizing antibodies against HIV shows promise in children

Eli Lilly expects to double planned employment in Boston center

STAT Readout Newsletter: Today's biggest biotech updates

Titanic submersible victims' family mourns: 'Enormous tragedy and devastation'

Submersible on Titanic tour reported missing off Newfoundland with 5 people aboard

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

How to save PrEP access — and even expand it

The PBM ad wars are taking over Washington, D.C.

Drug repurposing or repositioning? The language matters

Another man arrested in connection with shooting at Kansas nightclub

United colonoscopy coverage change 'may cost lives,' doctors say

US intelligence assessment says Iran not currently developing nuclear weapons

After affirmative action ruling, medical educators look to 'holistic review'

The PBM ad wars are taking over Washington, D.C.

United colonoscopy coverage change 'may cost lives,' doctors say

Father who lunged at Larry Nassar comforted by deputy who pinned him down: 'I understand'

focus

Submersible on Titanic tour reported missing off Newfoundland with 5 people aboard

Researchers explore possible ties between long Covid, menopause

US intelligence assessment says Iran not currently developing nuclear weapons

Father who lunged at Larry Nassar comforted by deputy who pinned him down: 'I understand'

Medicare reduced heart disease by changing how it pays doctors

Titanic submersible victims' family mourns: 'Enormous tragedy and devastation'

focus

focus

entertainment

focus